Literature DB >> 17076898

ADDP and PS-PPh3: an efficient Mitsunobu protocol for the preparation of pyridine ether PPAR agonists.

Paul S Humphries1, Quyen-Quyen T Do, David M Wilhite.   

Abstract

A series of pyridine ether PPAR agonists were synthesized through an ADDP and PS-PPh3 modified Mitsunobu protocol, which eliminated significant by-product formation. This method proved to be versatile, efficient and amenable to parallel synthesis.

Entities:  

Year:  2006        PMID: 17076898      PMCID: PMC1705810          DOI: 10.1186/1860-5397-2-21

Source DB:  PubMed          Journal:  Beilstein J Org Chem        ISSN: 1860-5397            Impact factor:   2.883


Findings

Peroxisome proliferator-activated receptors (PPARs) are pharmaceutical targets of great importance. Their wide-ranging effects on key transcriptional pathways for lipid handling, insulin sensitivity, inflammation and other functions have led to marketed drugs and vast clinical and preclinical research efforts.[1-11] In 1991, a series of PPAR analogues were disclosed, which for the first time did not contain a thiazolidine-2,4-dione pharmacophore.[12] These were propanoic acid derivatives with α-substitution to collectively serve as a mimic for the thiazolidine-2,4-dione ring. Based on the above and a knowledge of PPAR ligands publicly disclosed, we wished to synthesize compounds represented by the general structure 1 (Figure 1). Aromatic ethers are structural motifs found in many naturally occurring molecules and compounds of medicinal interest.[13] We envisaged the pyridyl ether moiety of 1 to be efficiently formed via Mitsunobu coupling of the requisite pyridinol and alkyl alcohols.[14-17]
Figure 1

Thiazolidine-2,4-dione mimic & chosen lead scaffold.

Thiazolidine-2,4-dione mimic & chosen lead scaffold. Our first attempt at the Mitsunobu reaction between pyridinol 2 and alcohol 3, utilizing a modification of the conditions originally reported by Mitsunobu,[18] afforded pyridyl ether 4 in 54% yield (Scheme 1). Interestingly, the reaction did not reach completion and pyridinol 2 was recovered, despite the fact that it was the limiting reagent. Upon closer examination, compound 5 was observed as a major by-product (46% based on 3).
Scheme 1

Reagents and conditions: (a) PS-PPh3, DEAD, THF, rt, 16 h, 54%.

Reagents and conditions: (a) PS-PPh3, DEAD, THF, rt, 16 h, 54%. By-products analogous to 5 have been observed in the literature when diethyl azodicarboxylate (DEAD) is used in certain Mitsunobu reactions.[18-19] This by-product formation is believed to be dependent on the pKa of the acidic component (e.g. 2).[18] If the phenol has a pKa > 11, the yield is considerably lower; and with the phenol having pKa > 13, the desired reaction does not occur. The hydrazo anion 6, in these cases, attacks the alkoxyphosphonium directly to afford alkylated hydrazine derivative 7 as the by-product (side reaction in Figure 2),[19] since anion 6 is not efficient in deprotonating the weakly acidic phenol.
Figure 2

Proposed mechanism of the Mitsunobu reaction.

Proposed mechanism of the Mitsunobu reaction. One way to improve the above redox system is to enhance the basicity of anion 6 by the replacement of the alkoxy group OEt in DEAD with strong electron donating groups such as NR2.[16] Thus, 1,1'-(azodicarbonyl)dipiperidine (ADDP),[20] 4,7-dimethyl-3,5,7-hexahydro-1,2,4,7-tetrazocin-3,8-dione (DHTD),[21] and N,N,N',N'-tetramethylazodicarboxamide (TMAD)[22] have been developed as new reagents in combination with tributyl phosphine (TBP). We initially chose ADDP, due to its commercial availability and low cost. The original reference utilized ADDP and TBP in benzene,[20] but due to safety and ease of handling we chose to keep PS-PPh3 and THF. Our first attempt was successful and no by-product 8 was observed in the reaction (Scheme 2) [see Supporting Information File 1 and Supporting Information File 2]. With the above result in hand, we then pursued a variety of targets by performing the modified Mitsunobu reaction of 2 and a variety of primary alcohols (Table 1). In general, a variety of diverse alcohols afforded the expected products in excellent yield. As expected, oxazoles, thiazoles, pyrazoles, and pyridines are tolerated in this chemistry. In a limited number of cases, functionality (e.g. basic amines, benzimidazoles, indoles, etc.) caused no reaction to occur and only recovered starting materials were isolated (data not shown).
Scheme 2

Reagents and conditions: (a) PS-PPh3, ADDP, THF, rt, 16 h, 81%.

Table 1

Modified Mitsunobu coupling of pyridinol 2 and a variety of primary alcoholsa

EntryAlcoholProductYield (%)EntryAlcoholProductYield (%)

198171579
2107881685
3118091777
41283101880
51371111972
61481122076

a Reactions were run using 0.5 mmol pyridinol, 0.55 mmol alcohol, 0.75 mmol PS-PPh3, 0.75 mmol ADDP and 5.5 mL tetrahydrofuran.

Reagents and conditions: (a) PS-PPh3, ADDP, THF, rt, 16 h, 81%. Modified Mitsunobu coupling of pyridinol 2 and a variety of primary alcoholsa a Reactions were run using 0.5 mmol pyridinol, 0.55 mmol alcohol, 0.75 mmol PS-PPh3, 0.75 mmol ADDP and 5.5 mL tetrahydrofuran. We then shifted our attention to variation of the pyridinol, whilst holding constant the 2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethanol reactant 3 (Table 2). As expected, variation of the 2-substituent of the pyridine ring resulted in equally high yields.
Table 2

Modified Mitsunobu coupling of alcohol 3 and a variety of pyridinolsa

EntryPyridinolProductYield (%)EntryPyridinolProductYield (%)

1218632384
2229542478

a Reactions were run using 0.5 mmol pyridinol, 0.55 mmol alcohol, 0.75 mmol PS-PPh3, 0.75 mmol ADDP and 5.5 mL tetrahydrofuran.

Modified Mitsunobu coupling of alcohol 3 and a variety of pyridinolsa a Reactions were run using 0.5 mmol pyridinol, 0.55 mmol alcohol, 0.75 mmol PS-PPh3, 0.75 mmol ADDP and 5.5 mL tetrahydrofuran. Having efficiently synthesized a diverse set of intermediate esters, we then sought an expedient method for obtaining the final carboxylic acids. We opted for a microwave-assisted procedure for this basic hydrolysis step. As shown in Scheme 3, the carboxylic acids (e.g. 25) could be obtained in a matter of minutes [see Supporting Information File 1 and Supporting Information File 2]. The significant reduction in reaction time resulted in a productivity enhancement due to increased sample processing. A number of the other esters described in this manuscript were also subjected to these conditions and all afforded the pure carboxylic acids in 82–100% yield.
Scheme 3

Reagents and conditions: (a) 1 N aq. NaOH, MeCN, 100°C μW, 10 mins, 96%.

Reagents and conditions: (a) 1 N aq. NaOH, MeCN, 100°C μW, 10 mins, 96%. In summary, we have developed a modified Mitsunobu protocol utilizing 1,1'-(azodicarbonyl)dipiperidine (ADDP) and polymer-supported triphenylphosphine (PS-PPh3). Employment of this method resulted in a rapid, convenient, and high-yielding two step protocol for the preparation of PPAR agonists. In particular, the modified Mitsunobu coupling of pyridinols and alcohols proved to be versatile, efficient and amenable to parallel synthesis. A full account of the medicinal chemistry of these compounds will be given elsewhere. Supporting Information. Experimental procedures and data for all novel compounds described in this manuscript. Auxiliary Data. Auxiliary data for all novel compounds described in this manuscript.
  8 in total

Review 1.  The PPARs: from orphan receptors to drug discovery.

Authors:  T M Willson; P J Brown; D D Sternbach; B R Henke
Journal:  J Med Chem       Date:  2000-02-24       Impact factor: 7.446

Review 2.  PPARs and the complex journey to obesity.

Authors:  Ronald M Evans; Grant D Barish; Yong-Xu Wang
Journal:  Nat Med       Date:  2004-04       Impact factor: 53.440

Review 3.  Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future.

Authors:  Daniel H van Raalte; Min Li; P Haydn Pritchard; Kishor M Wasan
Journal:  Pharm Res       Date:  2004-09       Impact factor: 4.200

Review 4.  Therapeutic significance of peroxisome proliferator-activated receptor modulators in diabetes.

Authors:  Vishnu Ji Ram
Journal:  Drugs Today (Barc)       Date:  2003-08       Impact factor: 2.245

Review 5.  1. Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands and their therapeutic utility.

Authors:  Brad R Henke
Journal:  Prog Med Chem       Date:  2004

Review 6.  Novel peroxisome proliferator-activated receptor ligands for Type 2 diabetes and the metabolic syndrome.

Authors:  Anne R Miller; Garret J Etgen
Journal:  Expert Opin Investig Drugs       Date:  2003-09       Impact factor: 6.206

Review 7.  Peroxisome proliferator-activated receptor-beta as a target for wound healing drugs.

Authors:  Nguan Soon Tan; Liliane Michalik; Béatrice Desvergne; Walter Wahli
Journal:  Expert Opin Ther Targets       Date:  2004-02       Impact factor: 6.902

Review 8.  Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis?

Authors:  Harrihar A Pershadsingh
Journal:  Expert Opin Investig Drugs       Date:  2004-03       Impact factor: 6.206

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.